Actor, Hodgkin's Survivor, To Star in New Show
US actor Brian Watson, best known for his role as Matt Camden in the television series "7th Heaven" returns to television in the title role of the new ABC series "What About Brian" this Sunday.
He was diagnosed with Hodgkin's lymphoma in May 2002, and went on hiatus acting in 7th Heaven while he sought treatment. While undergoing chemotherapy, he changed gears and joined the show's writing staff. "He's been inspirational" said 7th Heaven producer Brenda Hampton in a TV Guide interview at the time. He reportedly reached remission in April 2003, and he began appearing on the program again, starting with the 150th episode. He returned as a recurring cast member.
In What About Brian, Watson stars as Brian, a well-meaning guy who runs a video business called Zap Monkey. Brian is one of those guys who is loved by everyone except the girl he loves, Marjorie (Sarah Lancaster), who also is his best friend's girlfriend.
We're glad Watson has had a lasting remission and wish him the best in the new series.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
